Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomized, Two-armed, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of an Adjuvanted Recombinant SARS-CoV-2 Spike (S) Protein Subunit Vaccine Candidate (SpikoGen)

NCT05005559 is registered in ClinicalTrials.gov with Cinnagen as lead sponsor.

NCT NCT05005559
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05005559 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomized, Two-armed, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of an Adjuvanted Recombinant SARS-CoV-2 Spike (S) Protein Subunit Vaccine Candidate (SpikoGen)
Lead sponsor
Cinnagen
Phase
Phase 3
Overall status
Completed
Start date
August 7, 2021
Completion date
March 10, 2022
Enrollment
16,876 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid19